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Abstract
JC virus encephalopathy (JCVE) is a newly described gray matter disease of the brain caused by productive infection of
cortical pyramidal neurons. We characterized the full length sequence of JCV isolated from the brain of a JCVE patient,
analyzed its distribution in various compartments by PCR, and determined viral gene expression in the brain by
immunohistochemistry(IHC). We identified a novel JCV variant, JCVCPN1, with a unique 143 bp deletion in the Agno gene
encoding a truncated 10 amino acid peptide, and harboring an archetype-like regulatory region. This variant lacked one of
three nuclear protein binding regions in the Agno gene. It was predominant in the brain, where it coexisted with an Agno-
intact wild-type strain. Double immunostaining with anti-Agno and anti- VP1 antibodies demonstrated that the truncated
JCVCPN1 Agno peptide was present in the majority of cortical cells productively infected with JCV. We then screened 68 DNA
samples from 8 brain, 30 CSF and 30 PBMC samples of PML patients, HIV+ and HIV- control subjects. Another JCVCPN strain
with a different pattern of Agno-deletion was found in the CSF of an HIV+/PML patient, where it also coexisted with wild-
type, Agno-intact JCV. These findings suggest that the novel tropism for cortical pyramidal neurons of JCVCPN1, may be
associated with the Agno deletion. Productive and lytic infection of these cells, resulting in fulminant JCV encephalopathy
and death may have been facilitated by the co-infection with a wild- type strain of JCV.
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Introduction
The human polyomavirus JC (JCV) [1] is the cause of
widespread asymptomatic infection in healthy people [2]. Its
reactivation in immunosuppressed individuals may lead to
progressive multifocal leukoencephalopathy(PML), an often lethal
demyelinating disease of the brain. JCV has a circular double
stranded genomic DNA that includes a hypervariable non-coding
regulatory region (RR) and a very stable coding region encoding
the regulatory small t and large T antigens, and the capsid proteins
VP1, VP2 and VP3. It also encodes the Agnoprotein, which is
involved in viral DNA replication, RNA transcription and protein
expression [3,4,5].
Although JCV predominantly infects glial cells in the CNS, a
JCV-variant harboring a small deletion in the VP1 major capsid
protein, demonstrated specific tropism for cerebellar granule cell
neurons. Infection by this VP1-variant strain was associated with
cerebellar atrophy and neurologic dysfunction named JCV
granule cell neuronopathy (JCVGCN) [6,7,8,9]. Recently, we
have described a third clinical entity, distinct from PML and
JCVGCN, JCV encephalopathy (JCVE). This disease, described
in an HIV-negative patient with history of lung cancer treated
with chemotherapy, is caused by a productive JCV infection of
cortical pyramidal neurons. This patient presented with lesions
restricted to the hemispheric gray matter on MRI, developed
aphasia and progressive cognitive dysfunction and passed away 4
1/
2 month later [10].
We therefore investigated whether changes in JCV sequence
could be associated with the specific tropism to cortical pyramidal
neurons in this patient.
Results
JCVCPN1 has a deletion in the Agno gene and an
archetype-like regulatory region
The full length genome of JCV infecting cortical pyramidal
neurons(JCVCPN1, GenBank accession number JQ823124 or
BankIt1524974) was amplified from DNA extracted from the
fresh frozen right parietal lobe of the HIV-negative patient with
JCV encephalopathy(JCVE) [10]. The major mutation found in
this JCV strain is a 143 bp deletion starting from nt position 300 to
442 of the Agno gene, leaving a putative truncated Agnoprotein of
10 aa, with mutations in the last two aa (Fig. 1A). The regulatory
region(RR) of JCVCPN1 is an archetype-like RR or type II-S [11].
Compared to the archetype RR, JCVCPN1 RR has a 18 nt
deletion in the 98 bp element from nt 36–56, a 2 nt deletion in the
23 pb insert and an 80 bp insert in place of the 63 bp insert
present in the archetype. This 80 bp insert consist of two repeats of
the first 34 bp of the 66 bp insert linked by nt TA and followed by
the last 10 bp of the 66 bp insert (Fig. 1B). This finding is
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35793remarkable, since archetype or archetype-like RR is usually found
in JCV strains isolated from kidney or urine, and rarely from brain
samples. In addition, we found a total of 22 single nt mutations
scattered in the whole genome, 14 of them being silent mutations
(Table 1).
Figure 1. Genomic map and organization of regulatory region of JCVCPN1. A. The genomic map of JCVCPN1 shows a 143 bp deletion in the
Agno gene (nt 300–442), yielding a truncated 10 aa Agno peptide, the last two aa being mutated. B. Alignment of the regulatory region (RR) of
JCVCPN1 with the RR of prototype JCV Mad-1, usually found in CNS of PML patients and archetype JCV RR, most commonly found in urine of healthy
and immunosuppressed patients alike. JCVCPN1 has an archetype-like RR structure with a 19 bp deletion in the 98 bp element, a 3 nt deletion in the
23 bp insert and a complex mutation in the 66 bp insert, yielding a 80 bp insert. The whole nt sequence of the archetype 66 bp insert (*) and
corresponding changes in the 80 bp insert of JCVCPN1 RR (**) are indicated.
doi:10.1371/journal.pone.0035793.g001
Table 1. Single nucleotide mutations in JCVCPN1.
Amino acid mutations
Position Location Nucleotide mutation aa mutation
Mad1 CPN1 Mad1 CPN1
1100 VP2 G A S N192S
1689 VP1 A G N S74N
1692 VP1 G A R K75R
1850 VP1 A G T A128T
1940 VP1 C G L V158L
2502 VP1 A G K R345K
3035 T C T G V545G
4286 T T C F S128F
Silent Mutations
Position Location Nucleotide mutations
1086 VP2 A G
1843 VP1 G T
2245 VP1 C T
2260 VP1 A T
2311 VP1 G T
2518 VP1 G A
2592 Inter Coding G T
2712 T A G
3131 T T C
3134 T T C
3440 T T C
3545 T T C
3599 T G A
4095 T C A
5019 Early mRNA C T
doi:10.1371/journal.pone.0035793.t001
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brain of the patient with JCV encephalopathy
Two sets of primer pairs were designed to detect Agno-deleted,
JCVCPN1, and wild-type agno JCV strains in our clinical samples
(Fig. 2A). JCVCPN1 was the predominant JCV strain throughout
the brain. Indeed, the long fragment Agno PCR screening using
primer pair CPN1Ag45 and CPN1Ag43 capable of differentiating
Agno-deleted and Agno-intact JCV strains showed a strong signal
of Agno-deleted JCV variant in every brain DNA sample tested.
Conversely, JCV with wild-type Agno was only detected in right
frontal lobe DNA sample (Fig. 2B). To avoid underestimating the
presence of JCV with intact Agno due to the relatively low
sensitivity of the long fragment Agno primer pair CPN1Ag45 and
CPN1Ag43, we designed a more sensitive new set of primers,
CPN1Ag65 and CPN1Ag63, amplifying a shorter, 101 bp
fragment, that is only present in JCV strains with intact Agno
gene (short fragment Agno PCR screening). This screening
revealed the presence of JCV strain with intact Agno gene in
every brain DNA samples of this patient (Fig. 2C). These results
indicated that the predominant Agno-deleted JCVCPN1 strain
coexisted with a minority Agno-intact JCV species in the brain of
this patient.
JCV with intact Agno gene is present in CSF and blood of
the patient with JCV encephalopathy
To determine whether JCVCPN1 could cause systemic infection,
we screened the JCVE patient’s blood and CSF for the presence of
Agno-deleted JCV. Long fragment Agno PCR screening remained
entirely negative for both wild type and CPN type JCV strains
(data not shown), while JCV with intact Agno gene JCV could be
detected in the DNA extracted from plasma and CSF sample
(Fig. 2C). While the lower sensitivity of the long fragment Agno
PCR screening cannot allow us to formally rule out that a low
amount of Agno-deleted JCV was present in blood and CSF, these
results suggested that although JCVCPN1 was the major species in
the brain of this patient, systemic infection was carried out mainly
by an Agno-intact JCV strain.
Figure 2. Agno gene PCR screening of brain DNA samples from the patient with JCV encephalopathy. A. Schematic representation of
both the long fragment and short fragment Agno PCR screening. The long fragment Agno PCR screening was performed with primers CPN1Ag45
(4935–4958) and CPN1Ag43 (755–733), encompassing the entire Agno gene, and comprising a unique AccI restriction enzyme site. The short
fragment Agno PCR screening was performed with primers CPN1Ag65 (398–420) and CPN1Ag63 (498–472), the former being located within the
deleted section (300–442) of JCVCPN1. B. Long fragment Agno PCR screening result of Agno deletion in different brain DNA samples from JCVE
patient. A 951 bp fragment was amplified from JCV Mad1 strain which contained one AccI restriction enzyme site (414), while a 791 bp fragment
containing no AccI site could only be amplified from JCVCPN1. Two bands (341 bp and 610 bp) are visible after AccI digestion of the Mad-1 fragment
(Mad-1d), while AccI digestion of the JCVCPN1 fragment (JCVCPN1 d) shows no alteration of the 791 bp PCR product. After Acc I digestion, DNA
extracted from right frontal lobe showed the JCVCPN1 band and two digested bands coming from JCV with intact Agno gene, while all other brain
samples contained the JCVCPN1 fragment only that could not be digested with AccI. C: Short fragment Agno PCR screening result of intact Agno gene
in different brain DNA samples.A 101 bp fragment was amplified from JCV Mad-1 strains, which has an intact Agno gene, while no PCR product could
be amplified from JCVCPN1. An intact Agno fragment could be amplified from each brain sample tested, as well as from CSF and plasma, but not from
the PBMC sample from this patient. Abbreviations: d: digested by Acc I; R: right; L: left. CTRL: PCR control without DNA; PBMC: peripheral blood
mononuclear cells.
doi:10.1371/journal.pone.0035793.g002
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gray matter of the patient with JCVE
To determine whether the Agno-deleted JCVCPN1 mutant was
indeed responsible for the infection of cortical pyramidal neurons
of the patient with JCVE, we used two Agno protein Ab to stain
formalin fixed, paraffin embedded samples of this patient, and
from an HIV
+ patient with classic PML lesions as control. The first
Ab, anti-Agno1–71 raised against 3 peptides encompassing the
entire sequence of the Agnoprotein, can recognize the truncated
10 aa of JCVCPN1 Agno. The second Ab, anti-Agno48–71, detected
the C terminus of the Agnoprotein, and, therefore, can recognize
intact Agno protein, but cannot recognize the truncated 10 aa of
JCVCPN1 Agno, but only intact Agnoprotein.
As shown in Fig. 3 A, the anti-Agno1–71 staining was present in
all the cells also expressing the VP1 capsid protein (Fig. 3B,) in
affected cortical areas of the patient with JCVE. Insets # 1–3 show
the double staining of magnified cells. Conversely, most cortical
cells did not stain with the anti-Agno48–71 Ab (Fig. 3.C) and this
Ab did not colocalize with cells that also express VP1 (Fig. 3D).
Based on an average of 6 different blocks of cortical areas, only 1%
cells had double staining with the anti-Agno48–71 and VP1 Ab,
magnified in inset # 4, while 99% displayed VP1 staining only
(insets # 5 and 6). In classic PML lesions of an HIV
2infected
patient, however, both the anti-Agno1–71 and anti-Agno48–71 co-
stained most VP1-expressing cells equally (Fig. 4). These findings
suggest that the JCVCPN1 Agno-deletion variant was indeed the
major JCV species present in the cortical pyramidal neurons of the
patient with JCVE.
Agnoprotein-expressing cells in the gray matter of the
JCVE patient are neurons
To determine the phenotype of agnoprotein expressing cells in
the gray matter of the JCVE patient, double staining experiments
were performed using the anti-Agno1–71 ab and the neuronal
marker MAP-2. As shown in Fig. 5, numerous double stained cells-
could be seen in the cortical gray matter of the JCVE patient using
IFA (Fig. 5A–D). These results indicate that these cells were indeed
neurons. No double-stained cells could be seen using the anti-
Agno 48–71 ab and MAP-2 (data not shown), suggesting the
presence of a truncated Agnoprotein in these neurons. Similarly,
Figure 3. Double immunofluorescence staining of JC VP1 and Agnoprotein in JCVE patient. Double Immunofluorescence staining of JCV
VP1 capsid protein and two anti JCV-Agnoprotein antibodies in cortical hemispheric brain samples of the JCV encephalopathy patient. Anti-Agno1–71
staining (A, red channel) colocalizes with anti-VP1 staining (B, green channel) in the patient with JCVE and double-stained cells magnified in insets #
1–3 appear yellow-white after merging of red and green channels .Conversely, anti-Agno48–71 shows only limited staining (C, red channel) in this
patient with very rare colocalization with the anti-VP1 staining (D, green channel), magnified only in inset # 4, and the great majority of cells express
VP1 only (insets #5 and 6). Scale bar: 100 mm.
doi:10.1371/journal.pone.0035793.g003
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classic PML, using either anti-Agno ab (data not shown).
A different Agno-deleted JCVCPN variant is present in the
CSF of another patient with PML
To determine whether JCVCPN1 is a unique JCV variant
present only in our patient with JCVE, we screened 8 brain DNA
samples(from 5 PML/HIV
+ and 1 chronic lymphocytic leukemia/
HIV
2 patient), 30 CSF samples (20 PML/HIV
+, 1 PML/HIV
2,7
HIV
+ and 2 HIV
2 patients), and 30 PBMC DNA samples (10
PML/HIV
+, 10 PML/HIV
2, 2 HIV
2 immunosuppressed, 5
HIV
+ and 3 HIV
2 patients). Among all 68 clinical DNA samples
isolated from 63 patients, we found one Agno-deleted JCV strain
in one of the CSF samples of an HIV
+/PML patient, which we
named JCVCPN2 (Fig. 6A). This Agno-deleted JCV strain yielded a
530 bp amplification product by long PCR screening. Interest-
ingly, JCVCPN2 also coexisted with an Agno-intact JCV strain in
the CSF of this patient, as demonstrated by short fragment Agno
PCR screening, which could only detect undeleted JCV strains
(Fig. 6B). This sample was from a 35 year old male with AIDS and
Kaposi sarcoma, CD4
+ T cell counts of 84/ml and a plasma HIV
viral load of 124,000 copies/ml, who presented with left sided
ataxia and weakness. MRI showed cortical atrophy and a left
cerebellar and right posterior pontine lesion consistent with PML,
confirmed by positive CSF JCV PCR. Lesions stabilized on
combined anti-retroviral therapy. However, the patient passed
away 7 years later, from pneumonitis and sepsis unrelated to PML.
JCVCPN2 consisted of two different Agno-deleted
subtypes
Two different JCV subtypes were identified after long fragment
Agno PCR cloning and sequencing as shown in Fig. 7A. One
subtype, named JCVCPN2.1 which represented 90.5% of the total
JCV clones, had a 438 bp deletion starting at nt 248 in the late
promoter of the RR, encompassing the entire Agno gene and
terminating at nt 685 in the VP2 gene (Fig. 7A). The other
subtype, named JCVCPN2.2, which represented 9.5% clones, had a
403 bp deletion starting at nt 326 in the Agno gene, maintaining
the coding potential for a mutated 18 amino acid Agno peptide,
and ending at nt 728 in the VP2 gene (Fig. 7B). Both subtypes lost
Figure 4. Double immunofluorescence staining of JC VP1 and Agnoprotein in classic PML patient. Double Immunofluorescence staining
of JCV VP1 capsid protein and two anti JCV-Agnoprotein antibodies in brain autopsy samples of an HIV+ PML patient. Anti-Agno1–71 staining (A, red
channel) labels the same cells as anti-VP1 staining (B, green channel) in this patient with classic PML. Similarly, anti-Agno48–71 staining (C, red channel)
co-localizes with anti-VP1 staining (D, green channel). Magnified double-stained cells are shown in insets #1–3 and 4–6 after merging of red and
green channels. Scale bar: 100 mm.
doi:10.1371/journal.pone.0035793.g004
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to produce a VP2 protein. The aa sequence of the undeleted
Agnoprotein, the mutated 10 aa JCVCPN1 and 18 aa JCVCPN2.2
Agno deletion variants are shown in figure 7B.
The Agno-deletion mutant JCVCPN2 has RR with tandem
repeat pattern
To determine whether JCVCPN2 had an archetype-like RR
similar to JCVCPN1, we sequenced its RR contained in the long
Agno PCR fragment and compared it to JCV prototype Mad-1,
archetype RR, and JCVCPN1 RR (Fig. 8). Compared to JCVCPN1,
the RR had a partial duplication of the 98 bp element and
truncated inserts, corresponding to a type II-R [11]. JCVCPN2.1
had two different types of RR. The main type called JCVCPN2.11,
accounted for 88.6% (93/105) of the tested clones, consisted of two
incomplete 98 bp elements, the second of which contained the
23 bp insert truncated to 3 bp, and an intact 66 bp insert (Fig. 8).
A minority RR type, called JCVCPN2.12 accounting for 1.9% of
clones was similar to JCVCPN2.11 but also had 23 bp insert
truncated to 22 bp in the first 98 bp element. Finally, JCVCPN2.2
had a single type of RR, which was similar to JCVCPN2.12, but had
a different deletion in the late promoter. These results indicated
that Agno-deleted JCV variants may not necessarily have an
archetype-like RR, and can also have RR with tandem repeat
pattern, more commonly found in the CNS of patients with PML.
Nuclear protein binding regions are important for viral JCV
DNA replication. Indeed the intact JCV Agno gene contains three
nuclear protein binding regions. These are named region I: nt 458
to 475; II: nt 442 to 457, and III: nt 350–411 [5]. In JCVCPN1,
binding region I was preserved, region II had a single nucleotide
deletion, and region III was completely deleted. However, all
Figure 5. Double immunofluorescence staining of neuronal marker and JC Angoprotein in JCVE patient. Double immunostaining of
Agnoprotein and a neuronal marker in the cortical hemispheric brain sample of the JCV encephalopathy patient. Many cells display both anti-Agno1–
71 staining (red) and MAP-2 (green, panels A–D, arrows) and can be visualized in the insets with the red and green channels. These cells are
interspersed among non-infected neurons (panels A–D, arrowheads) Scale bar: is 25 mm.
doi:10.1371/journal.pone.0035793.g005
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(Fig. 8).
Discussion
This HIV-negative patient with JCVE had a unique 143 bp
deletion in the JCV Agno gene, resulting in a truncation from 71
to 10 amino acids, and leading to productive infection of cortical
pyramidal neurons. Although a wild-type JCV strain coexisted in
all compartments, and was the only one found outside the brain
parenchyma, immunostaining with two different Ab confirmed
that almost all cells productively infected with JCV in the gray
matter expressed the truncated agnoprotein. Since no such Agno
deletion had ever been reported among more than 400 full length
JCV sequences deposited in GenBank, we called this novel isolate
JCVCPN1.
How could such an Agno-deletion mutant enter and replicate in
cortical pyramidal neurons? The JCV Agno gene has been shown
to have regulatory functions which impact JCV propagation in
vitro. Indeed, three nuclear protein binding regions have been
identified in the Agno gene. Whereas, the loss of Agno protein,
due to mutations in the initiation codon, only resulted in a slight
decrease in the JCV replication, the deletion of the entire Agno
gene resulted in significant decrease of JCV replication [5]. Hence,
although the protein factors which bind to the Agno gene are still
unknown, there is supporting evidence that the Agno gene
sequence serves as a cis-acting regulatory element in JCV DNA
replication. In JCVCPN1, the 143 bp deletion only removed
binding region III, while region I was preserved and region II
had only a single nucleotide deletion. These findings may explain
why JCVCPN1 was able to keep replicating in the cortical neurons
of this patient.
Knowledge of the Agnoprotein’s function is limited. This
protein can be phosphorylated by protein kinase C [12], and
dephosphorylated by protein phosphatase 2A [13]. Dephosphor-
ylated Agnoprotein has been localized in the nucleus and its
phosphorylated form was detected in the cytoplasm [4]. In the
nucleus, Agnoprotein can bind to heterochromatin protein 1(HP1)
and induce disassociation of HP1 from lamin B receptor and
therefore make the nuclear envelope permissible for transportation
of JCV virions [14]. In the cytoplasm, Agnoprotein can bind both
fasciculation and elongation protein zeta 1 as well as microtubules
and thereby promote the spread of JCV virions to uninfected
adjacent cells [15]. Agnoprotein also has impact on both early and
late protein expression of JCV in host cells. Deletion of the Agno
gene from JCV genome resulted in decreased expression of both
large T-antigen and VP1 protein [4,5]. Therefore, the Agnopro-
tein plays an important role in propagation of JCV through both
regulation of early and late gene transcription, and the control of
virion transport. It has also been postulated that the Agnoprotein
belongs to the viroporin family, which allow the exit of mature
virions out of the cells [16]. Since JCVCPN1 does not express a fully
functional Agnoprotein, this virus may therefore replicate at low
levels in the nucleus of cortical pyramidal neurons, but is unable to
exit these cells and spread efficiently. Because neurons do not
express MHC class I proteins, the virus may escape recognition by
the immune system. At some point, productive infection of
neurons may have been triggered by the availability of intact
Agnoprotein delivered in trans by wild-type JCV co-infection,
causing cell lysis and associated neurological dysfunction. In
addition, it is also possible that the mounting viral burden may
have triggered local inflammation and lead to immune recognition
of infected neurons.
How JCVCPN1 did enter cortical pyramidal neurons is unclear.
Indeed, JCV has a restricted host-cell range and mainly infects
glial cells in the CNS. Furthermore, this virus did not harbor the
deletion in the VP1 C terminus previously detected in JCVGCN1,
an isolate found in cerebellar granule cell neurons [6,8]. It is
therefore possible that JCV may enter a large variety of cells, and
that the Agno deletion allows preferential accumulation in cortical
pyramidal neurons, whereas Agno- intact strains remain mainly in
glial cells. Alternatively, it is possible that a primary infection with
JCVCPN1, occurring in this immunosuppressed individual, led to
the diffuse cortical involvement observed in this patient. We have
previously observed a similar histological pattern of neuronal
infection in immunossuppressed monkeys inoculated with a
neurotropic strain of SV40 [17]. In support of this hypothesis,
this patient had anti-JCV IgG, IgM and IgA in her serum at the
time of symptom onset [10]. Whether infection with Agno-intact
JCV occurred simultaneously or sequentially in this patient cannot
be answered by our study, because of the lack of premorbid
samples. Another explanation for the neuronal tropism of
JCVCPN1 may come from its RR. Indeed, the RR has long been
identified to have a crucial role in the entry of JCV in the CNS
and development of PML. However, the RR of JCVCPN1 has an
archetype-like structure, which is usually found in urine and
Figure 6. Identification of JCVCPN2 in other CSF samples by
PCR. Agno gene PCR screening of 11 CSF DNA samples reveals another
Agno deletion variant. A. Long fragment Agno PCR screening result of
Agno deletion in different brain DNA samples. Compared with the
951 bp fragment amplified from Agno-intact JCV and 791 bp from
JCVCPN1, a shorter ,530 bp fragment was amplified from 1/11 CSF DNA
samples tested, which was named JCVCPN2; B. Short PCR screening
result showed the presence of an intact Agno JCV strain in the same
CSF sample.
doi:10.1371/journal.pone.0035793.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35793Figure 7. Comparison of JCVCPN1 and JCVCPN2 Agno gene organization and their final expression product. A. Alignment of the Agno
gene structure of JCV prototype Mad-1, which has an intact Agno gene, JCVCPN1 which has a 143 bp Agno deletion and the two subtypes of JCVCPN2
which have a 438 and 403 bp deletion in Agno and VP2. Nuclear protein binding regions are indicated B. Alignment of the aminoacid structure of the
JCV prototype Mad-1 Agnoprotein, with the 10 aa of JCVCPN1 and 18 aa of JCVCPN2.2. JCV CPN2.1 cannot express any Agno product.
doi:10.1371/journal.pone.0035793.g007
Figure 8. Comparison of different kinds of organization of JCV regulatory regions. Comparison of the regulatory regions (RR) of JCV
prototype Mad-1, JCV archetype, JCVCPN1 and the JCVCPN2 subtypes.
doi:10.1371/journal.pone.0035793.g008
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the CNS of PML patients. Although we have recently shown that
this distinction is not absolute [18], it still seems more likely that
the neuronal tropism of JCVCPN1 was caused by its coding region
rather than its RR.
The finding of another Agno-deletion mutant, JCVCPN2, which
coexisted with an Agno-intact JCV strain in the CSF of an HIV
+/
PML patient, suggests that such variants occur in nature and have
been previously overlooked. Unlike JCVCPN1, JCVCPN2 was
constituted of two subtypes based on its coding region, involving
deletions extending to the VP2 gene leading to a total absence of
the Agnoprotein, or an Agnoprotein truncated to 18 aa, in
addition to a lack of VP2 capsid protein. Unlike JCVCPN1, the RR
of JCVCPN2 subtypes was of type II-R [11] with a tandem repeat
pattern usually found in the CNS of PML patients, indicating that
the composition of the RR is not necessarily associated with
mutations of the Agno gene. This HIV
+/PML patient had classic
PML lesions as well as cortical atrophy on MRI, but no clinical
evidence of JCVE. Since no cortical samples were available for
histological examination, it is not possible to determine whether
JCVCPN2 was a functionally replicating virus that could also infect
neurons.
Over the past few years, the range of individuals at risk of PML
has widened, and now also includes patients with autoimmune
diseases treated with immunomodulatory medications. These
include natalizumab for multiple sclerosis [19] and Crohn’s [20]
disease, efalizumab for psoriasis [21] and rituximab for rheuma-
tologic conditions [22]. We have recently shown that JCV
infection of cortical neurons occurs in up to half of the PML
patients with lesions located in the gray matter of the gray-white
junction [23]. Molecular studies of JC virus strains present in these
areas are in progress in our laboratory. Identification of other
JCVE cases will be necessary to confirm our findings. Therefore,
clinicians should be aware that in addition to PML, immunocom-
promised patients may also be at risk for isolated gray matter
lesions caused by JCV-deletion variants.
Materials and Methods
The patients gave written consent to participate in this study
according to guidelines of the Beth Israel Deaconess Medical
Center (BIDMC) Committee on Clinical Investigations. The
BIDMC Committee on Clinical Investigations specifically ap-
proved this study.
DNA extraction and Quantitative PCR (QPCR) analysis of
JCV viral load in brain autopsy samples
QIAamp DNA Blood Mini Kit (QIAGEN, Maryland, USA)
was used to extract DNA from fresh frozen autopsy brain samples.
All nucleotide (nt) positions of primers and probes correspond to
the JCV prototype Mad-1 sequence. 0.5 mg brain DNA served as
template in QPCR analysis. We used primer pair: JP25 (59-
CTGGTGAATTTATAGAAAGAAGTATTGCA-39, nt 1343–
1371) and JP23 (59-GGGCCATCTTCATATGCTTCAA-39,n t
1475–1454), and probe JCVP2Probe (6FAM-ATCTGCTCCT-
CAATGGATGTTGCCTTTACTT-TAMRA, nt 1392–1422
Applied Biosystems, Foster City, CA,) located in the VP2 gene.
QPCR reaction was performed in duplicate by using 0.5 mg
extracted brain DNA, 10 pmol of each primer, 2.5 pmol probe,
7.5 pmol reference dye (Rox), and 12.5 ml of TagMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA) in a final
volume of 25 ml. The cycles of amplification consisted of 2 min of
50uC, and an activation step of 10 min at 94uC, followed by 40
cycles of 94uC for 15 sec, 60uC for 1 min. QPCR was performed
using 7300 Real Time PCR System (Applied Biosystems, Foster
City, CA).
Full length PCR amplification of the entire genome of
JCVCPN1
JCV full length PCR was performed as previously described [1].
A complete JCV molecular clone was sequenced, and was named
JCV cortical pyramidal neurons type 1.
Long fragment Agno PCR screening of JCVCPN1 deletion
in clinical samples
We used primer pair CPN1Ag45 (59-TGTTCCCCCATGCA-
GACCTATCAA-39, nt 4935–4958) and CPN1Ag43 (59-
GCCCCCGGAGCTCCAGTTATTAC-39 nt 755–733) to detect
the presence of a deletion in Agno gene in various clinical DNA
samples. With this pair of primers, a long 951 bp DNA fragment
can be amplified from undeleted JCV strains (such as in the JCV
Mad-1 prototype), which contains one AccI restriction enzyme site
at nt 414 located in the region of the Agno gene that is deleted in
JCVCPN1 (nt 300–442 of Mad-1 strain). After digestion by AccI
(New England Biolabs, Ipswich, MA, USA), the 951 bp fragment
amplified from intact JCV genomes is cut in two fragments of
610 bp and 341 bp. Conversely, a 791 bp DNA fragment is
amplified from the Agno deletion-mutant JCVCPN1, which lacks
this AccI site, and therefore remains intact after AccI digestion.
The cycles of amplification consisted of 10 min of 94uC pre-
activation step, followed by 40 cycles of 94uC for 15 sec, 60uC for
30 sec, and 72uC for 1 min, and a final step of 72uC for 15 min.
Short fragment Agno PCR screening of undeleted JCV
strains in clinical samples
We used primer pair: CPN1Ag65 (59-CAGGTGAAGA-
CAGTGTAGACGGG-39, nt 398–420) and CPN1Ag63 (59-
ACTTACCTATGTAGCTTTTGGTTCAGG-39, nt 498–472)
to amplify a short, 101 bp fragment encompassing the C terminus
of the Agno gene and the N terminus of the VP2 gene. Since primer
CPN1Ag65 is located in the deleted Agno sequence of JCVCPN1,n o
PCR product could be amplified from JCVCPN1 strain. The cycles
of amplification consisted of 10 min of 94uC pre-activation step,
followed by 40 cycles of 94uC for 15 sec, 60uC for 15 sec, and 72uC
for 30 sec, with a final step of 72uC for 15 min.
Immunostaining of Agnoprotein in hemispheric cortex
We used the following primary antibodies (Ab) in immunohis-
tochemistry (IHC) experiments: Mouse monoclonal anti-
VP1(PAB597) [24], Rabbit Polyclonal anti-JCV Agnoprotein Ab
(a generous gift of Dr Mahmut Safak) [25] and rabbit polyclonal
anti JCV Agnoprotein C terminus Ab [26]. We will refer to those
two anti-Agnoprotein Ab as anti-Agno1–71 and anti-Agno48–71
respectively.
Double immunofluorescence (IF) stainings were performed with
primary Abs PAB597, anti-Agno1–71 and anti-Agno48–71 Ab and
anti-neuronal chicken Ab MAP-2 (Lifespan Bioscience, Seattle,
WA), secondary Abs are Alexa Fluor 488 & 568 conjugated Goat
anti mouse and/or rabbit secondary Ab (Invitrogen) [23].
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